Cardiorenal effects of SGLT2 inhibitors: who might benefit?

Abstract

Sodium glucose co-transporter-2 inhibitors have been shown to have multiple cardiovascular and renal benefits in patients with type 2 diabetes. In large randomised controlled trials they reduced major cardiovascular outcomes, hospitalisation for heart failure and adverse kidney outcomes, independently of their glucose-lowering effects. They are simple to prescribe and do not require dose titration. Compelling indications for this class of medications in patients with type 2 diabetes include those at high or very high risk of cardiovascular events and those with established atherosclerotic cardiovascular disease. They are also indicated for patients with heart failure and chronic kidney disease, regardless of diabetic status.